<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
Ultrahigh resolution drug design I: Details of interactions in human aldose reductase–inhibitor complex at 0.66 Å

doi: 10.1002/prot.20015
pmid: 15146478
Ultrahigh resolution drug design I: Details of interactions in human aldose reductase–inhibitor complex at 0.66 Å
AbstractThe first subatomic resolution structure of a 36 kDa protein [aldose reductase (AR)] is presented. AR was cocrystallized at pH 5.0 with its cofactor NADP+ and inhibitor IDD 594, a therapeutic candidate for the treatment of diabetic complications. X‐ray diffraction data were collected up to 0.62 Å resolution and treated up to 0.66 Å resolution. Anisotropic refinement followed by a blocked matrix inversion produced low standard deviations (<0.005 Å). The model was very well ordered overall (CA atoms' mean B factor is 5.5 Å2). The model and the electron‐density maps revealed fine features, such as H‐atoms, bond densities, and significant deviations from standard stereochemistry. Other features, such as networks of hydrogen bonds (H bonds), a large number of multiple conformations, and solvent structure were also better defined. Most of the atoms in the active site region were extremely well ordered (mean B ∼3 Å2), leading to the identification of the protonation states of the residues involved in catalysis. The electrostatic interactions of the inhibitor's charged carboxylate head with the catalytic residues and the charged coenzyme NADP+ explained the inhibitor's noncompetitive character. Furthermore, a short contact involving the IDD 594 bromine atom explained the selectivity profile of the inhibitor, important feature to avoid toxic effects. The presented structure and the details revealed are instrumental for better understanding of the inhibition mechanism of AR by IDD 594, and hence, for the rational drug design of future inhibitors. This work demonstrates the capabilities of subatomic resolution experiments and stimulates further developments of methods allowing the use of the full potential of these experiments. Proteins 2004. © 2004 Wiley‐Liss, Inc.
- University of Göttingen Germany
- Institute of Pharmacology and Structural Biology France
- Centre national de la recherche scientifique France
- Institute for Diabetes Discovery United States
- Science Applications International Corporation (United States) United States
Models, Molecular, Binding Sites, Molecular Structure, Protein Conformation, Electrons, Acetates, Crystallography, X-Ray, Thioamides, Aldehyde Reductase, Thiocarbamates, Drug Design, Solvents, Enzyme Inhibitors, Hydrogen
Models, Molecular, Binding Sites, Molecular Structure, Protein Conformation, Electrons, Acetates, Crystallography, X-Ray, Thioamides, Aldehyde Reductase, Thiocarbamates, Drug Design, Solvents, Enzyme Inhibitors, Hydrogen
3 Research products, page 1 of 1
- 2019IsRelatedTo
- 2003IsRelatedTo
- 2003IsSupplementTo
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).288 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%